GSK States Scientific Consensus Finds No Consistent Evidence Linking Zantac (Ranitidine) To Cancer; No Settlement Or Payment Made In Ms. Kasza's Voluntary Dismissal
Portfolio Pulse from Benzinga Newsdesk
GSK announced that scientific consensus finds no consistent evidence linking Zantac (Ranitidine) to cancer. Additionally, no settlement or payment was made in Ms. Kasza's voluntary dismissal.
June 10, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK announced that scientific consensus finds no consistent evidence linking Zantac (Ranitidine) to cancer. Additionally, no settlement or payment was made in Ms. Kasza's voluntary dismissal.
The announcement that there is no consistent evidence linking Zantac to cancer and the voluntary dismissal of Ms. Kasza's case without settlement or payment is likely to have a positive short-term impact on GSK's stock price. This news alleviates some legal and reputational risks associated with Zantac.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100